Literature DB >> 16815199

Postoperative radiation therapy for T1 and T2 primary parotid carcinoma: is it useful?

Peter Zbären1, Michel Nuyens, Marco Caversaccio, Richard Greiner, Edouard Stauffer.   

Abstract

OBJECTIVE: The benefit of postoperative radiation for advanced primary parotid carcinoma has been reported previously, whereas studies to evaluate the usefulness of postoperative radiation for T1 and T2 parotid carcinomas have never been performed. STUDY DESIGN AND
SETTING: Retrospective analysis on 58 previously untreated patients with T1 and T2 parotid carcinomas. In 34 patients, postoperative radiation was included in the treatment protocol and in 24 patients, no postoperative radiation was applied.
RESULTS: A local recurrence was observed in 8 of 24 (33%) patients without and in 1 of 34 (3%) patients with postoperative radiation (P < 0.5). The 5-year actuarial and disease-free survival rate was 83% and 70% for patients without postoperative radiation and 93% and 92% for patients with postoperative radiation. CONCLUSION AND SIGNIFICANCE: Local recurrence was less often observed in patients with postoperative radiation. Nevertheless, prospective randomized studies are needed to confirm the usefulness of postoperative radiation in early carcinomas. EBM RATING: B-3b.

Entities:  

Mesh:

Year:  2006        PMID: 16815199     DOI: 10.1016/j.otohns.2006.03.007

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  3 in total

1.  [2014: activation of OPS 8-980 "Complex intensive care treatment" by DIMDI].

Authors:  L Engelmann
Journal:  Med Klin Intensivmed Notfmed       Date:  2013-12-20       Impact factor: 0.840

2.  Analysis of prognostic risk factors and treatment of parotid cancer.

Authors:  Jinbiao Shang; Yingjie Wu; Wendong Wang; Kejing Wang; Minghua Ge
Journal:  Oncol Lett       Date:  2012-04-02       Impact factor: 2.967

3.  125I seed implant brachytherapy for the treatment of parotid gland cancers in children and adolescents.

Authors:  L Zheng; J Zhang; T Song; J Zhang; G Yu; Y Zhang
Journal:  Strahlenther Onkol       Date:  2013-03-23       Impact factor: 3.621

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.